Simtuzumab has shown limited efficacy in patients with pancreatic cancer or KRAS-mutant colorectal cancer (47, 48), which may be due to the indirect and weak blocking effect of simtuzumab on the interaction of LOXL2 with PEAR1. Here, KRAS is linked to familial pancreatic carcinoma.